A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

Inclusion Criteria:

1. Histologically documented treatment-naive Stage I (T < 4 cm, AJCC 8th ed)adenocarcinoma NSCLC

2. Complete surgical resection (R0) of the primary NSCLC

3. Unequivocal no evidence of disease at post-surgical

4. Pre-surgical ctDNA-positive result (Stage IA or IB) OR presence of at least onehigh-risk pathological feature (visceral pleural invasion (VPI), lymphovascularinvasion (LVI), high-grade histology) (Stage IB only)

5. ECOG of 0 or 1, life expectancy of > 6 months and complete recovery after surgery

6. Adequate bone marrow reserve and organ function

Exclusion Criteria:

1. Sensitizing EGFR mutation and/or ALK alteration

2. History of non-infectious ILD/pneumonitis that required steroids, has currentILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out byimaging at screening

3. Significant pulmonary function compromise

4. History of another primary malignancy within 3 years (with exceptions)

5. Any evidence of severe or uncontrolled systemic diseases, including but not limitedto bleeding diseases, active infection and cardiac disease

6. Active or prior documented autoimmune or inflammatory disorders (with exceptions)

7. Active infection with tuberculosis, hepatitis B or C virus, hepatitis A, or knownHIV infection that is not well controlled

8. History of active primary immunodeficiency

9. Clinically significant corneal disease